- Home
- DBRG vs AZTA Comparison
DBRG vs AZTA Comparison
Compare DBRG & AZTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DBRG
- AZTA
- Stock Information
- Founded
- DBRG 1991
- AZTA 1978
- Country
- DBRG United States
- AZTA United States
- Employees
- DBRG N/A
- AZTA N/A
- Industry
- DBRG Real Estate Investment Trusts
- AZTA Industrial Machinery/Components
- Sector
- DBRG Real Estate
- AZTA Technology
- Exchange
- DBRG Nasdaq
- AZTA Nasdaq
- Market Cap
- DBRG 2.0B
- AZTA 2.4B
- IPO Year
- DBRG 2009
- AZTA 1995
- Fundamental
- Price
- DBRG $12.15
- AZTA $44.75
- Analyst Decision
- DBRG Strong Buy
- AZTA Buy
- Analyst Count
- DBRG 9
- AZTA 4
- Target Price
- DBRG $16.67
- AZTA $58.75
- AVG Volume (30 Days)
- DBRG 2.6M
- AZTA 546.3K
- Earning Date
- DBRG 02-20-2025
- AZTA 02-05-2025
- Dividend Yield
- DBRG 0.33%
- AZTA N/A
- EPS Growth
- DBRG N/A
- AZTA N/A
- EPS
- DBRG 0.07
- AZTA N/A
- Revenue
- DBRG $607,028,000.00
- AZTA $662,108,000.00
- Revenue This Year
- DBRG N/A
- AZTA N/A
- Revenue Next Year
- DBRG N/A
- AZTA $6.29
- P/E Ratio
- DBRG $67.56
- AZTA N/A
- Revenue Growth
- DBRG N/A
- AZTA 5.36
- 52 Week Low
- DBRG $10.04
- AZTA $38.82
- 52 Week High
- DBRG $19.49
- AZTA $67.77
- Technical
- Relative Strength Index (RSI)
- DBRG 65.50
- AZTA 31.74
- Support Level
- DBRG $10.04
- AZTA $43.93
- Resistance Level
- DBRG $12.63
- AZTA $46.10
- Average True Range (ATR)
- DBRG 0.56
- AZTA 2.60
- MACD
- DBRG 0.19
- AZTA -0.77
- Stochastic Oscillator
- DBRG 81.50
- AZTA 7.00
About DBRG DigitalBridge Group Inc.
DigitalBridge Group Inc is a developer of alternative asset manager dedicated to investing in digital infrastructure. The company's platform invests in and operates businesses across the digital ecosystem, including cell towers, data centers, fiber, small cells, and edge infrastructure, to provide clients with funds for digital infrastructure real estate infrastructure.
About AZTA Azenta Inc.
Azenta Inc is a provider of life sciences solutions, enabling impactful breakthroughs and therapies to market faster. It provides a full suite of reliable cold-chain sample management solutions and genomic services across areas such as drug development, clinical research and cell therapies for the industry's top pharmaceutical, biotech, academic and healthcare institutions globally. The company has three reportable segments that are Sample Management Solutions, Multiomics, and B Medical Systems. It generates a substantial part of its revenue from its Sample Management Solutions segment.